Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Depreciation & Amortization (CF): 2019-2025

Historic Depreciation & Amortization (CF) for Fulcrum Therapeutics (FULC) over the last 7 years, with Sep 2025 value amounting to $300,000.

  • Fulcrum Therapeutics' Depreciation & Amortization (CF) fell 25.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year decrease of 23.56%. This contributed to the annual value of $1.6 million for FY2024, which is 27.27% down from last year.
  • Fulcrum Therapeutics' Depreciation & Amortization (CF) amounted to $300,000 in Q3 2025, which was down 0.00% from $300,000 recorded in Q2 2025.
  • Fulcrum Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $700,000 during Q2 2021, with a 5-year trough of $300,000 in Q2 2025.
  • Moreover, its 3-year median value for Depreciation & Amortization (CF) was $400,000 (2025), whereas its average is $443,273.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first climbed by 20.00% in 2021, then crashed by 33.33% in 2024.
  • Quarterly analysis of 5 years shows Fulcrum Therapeutics' Depreciation & Amortization (CF) stood at $615,000 in 2021, then dropped by 3.90% to $591,000 in 2022, then decreased by 15.40% to $500,000 in 2023, then decreased by 24.80% to $376,000 in 2024, then decreased by 25.00% to $300,000 in 2025.
  • Its last three reported values are $300,000 in Q3 2025, $300,000 for Q2 2025, and $400,000 during Q1 2025.